NEUROCRINE BIOSCIENCES INC Equity Securities, FV-NI, Unrealized Gain (Loss)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $1.20M.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $25.30M.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $2.70M.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $30.60M.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$4.00M.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$37.10M, a 230.63% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $28.40M, a 7.79% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $30.80M, a 47.37% increase from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-07-31 | $26.50M 10-Q · filed 2026-07-31 | $29.20M derived: sum of 3 quarters · filed 2026-07-31 | $59.80M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2026-03-31 | $25.30M 10-Q · filed 2026-05-05 | $28.00M derived: sum of 2 quarters · filed 2026-05-05 | $58.60M derived: sum of 3 quarters · filed 2026-05-05 | $51.90M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $33.30M derived: sum of 2 quarters · filed 2026-02-11 | $26.60M derived: sum of 3 quarters · filed 2026-07-31 | -$4.00M 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $30.60M 10-Q · filed 2025-10-28 | $23.90M derived: sum of 2 quarters · filed 2026-07-31 | -$6.70M 10-Q · filed 2025-10-28 | -$8.60M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-06-30 | -$6.70M 10-Q · filed 2026-07-31 | -$37.30M 10-Q · filed 2026-07-31 | -$39.20M derived: sum of 3 quarters · filed 2026-07-31 | -$56.10M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-03-31 | -$30.60M 10-Q · filed 2026-05-05 | -$32.50M derived: sum of 2 quarters · filed 2026-05-05 | -$49.40M derived: sum of 3 quarters · filed 2026-05-05 | -$69.30M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$18.80M derived: sum of 2 quarters · filed 2026-02-11 | -$38.70M derived: sum of 3 quarters · filed 2026-02-11 | -$37.10M 10-K · filed 2026-02-11 | |||
| 2024-09-30 | -$16.90M 10-Q · filed 2025-10-28 | -$36.80M derived: sum of 2 quarters · filed 2025-10-28 | -$35.20M 10-Q · filed 2025-10-28 | -$6.20M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-06-30 | -$19.90M 10-Q · filed 2025-07-30 | -$18.30M 10-Q · filed 2025-07-30 | $10.70M derived: sum of 3 quarters · filed 2026-02-11 | -$29.40M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-03-31 | $1.60M 10-Q · filed 2025-05-05 | $30.60M derived: sum of 2 quarters · filed 2026-02-11 | -$9.50M derived: sum of 3 quarters · filed 2026-02-11 | $27.80M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2023-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$11.10M derived: sum of 2 quarters · filed 2026-02-11 | $26.20M derived: sum of 3 quarters · filed 2026-02-11 | $28.40M 10-K · filed 2026-02-11 | |||
| 2023-09-30 | -$40.10M 10-Q · filed 2024-10-30 | -$2.80M derived: sum of 2 quarters · filed 2024-10-30 | -$600.00K 10-Q · filed 2024-10-30 | $6.60M derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2023-06-30 | $37.30M 10-Q · filed 2024-08-01 | $39.50M 10-Q · filed 2024-08-01 | $46.70M derived: sum of 3 quarters · filed 2025-02-10 | $57.80M derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2023-03-31 | $2.20M 10-Q · filed 2024-05-01 | $9.40M derived: sum of 2 quarters · filed 2025-02-10 | $20.50M derived: sum of 3 quarters · filed 2025-02-10 | $13.10M derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2022-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $18.30M derived: sum of 2 quarters · filed 2025-02-10 | $10.90M derived: sum of 3 quarters · filed 2025-02-10 | $30.80M 10-K · filed 2025-02-10 | |||
| 2022-09-30 | $11.10M 10-Q · filed 2023-10-31 | $3.70M derived: sum of 2 quarters · filed 2023-10-31 | $23.60M 10-Q · filed 2023-10-31 | $52.00M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-06-30 | -$7.40M 10-Q · filed 2023-08-01 | $12.50M 10-Q · filed 2023-08-01 | $40.90M derived: sum of 3 quarters · filed 2024-02-09 | $32.70M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-03-31 | $19.90M 10-Q · filed 2023-05-03 | $48.30M derived: sum of 2 quarters · filed 2024-02-09 | $40.10M derived: sum of 3 quarters · filed 2024-02-09 | $40.10M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2021-12-31 | $28.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $20.20M derived: sum of 2 quarters · filed 2024-02-09 | $20.20M derived: sum of 3 quarters · filed 2024-02-09 | $20.90M 10-K · filed 2024-02-09 | |||
| 2021-09-30 | -$8.20M 10-Q · filed 2022-11-01 | -$8.20M derived: sum of 2 quarters · filed 2022-11-01 | -$7.50M 10-Q · filed 2022-11-01 | -$13.00M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $700.00K 10-Q · filed 2022-08-04 | -$4.80M derived: sum of 3 quarters · filed 2023-02-09 | -$11.80M derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-04 | -$4.80M derived: sum of 2 quarters · filed 2023-02-09 | -$11.80M derived: sum of 3 quarters · filed 2023-02-09 | -$500.00K derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2020-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$12.50M derived: sum of 2 quarters · filed 2023-02-09 | -$1.20M derived: sum of 3 quarters · filed 2023-02-09 | -$17.70M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | -$7.00M 10-Q · filed 2021-11-01 | $4.30M derived: sum of 2 quarters · filed 2021-11-01 | -$12.20M 10-Q · filed 2021-11-01 | -$19.40M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2020-06-30 | $11.30M 10-Q · filed 2021-08-03 | -$5.20M 10-Q · filed 2021-08-03 | -$12.40M derived: sum of 3 quarters · filed 2022-02-11 | -$40.90M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2020-03-31 | -$16.50M 10-Q · filed 2021-05-05 | -$23.70M derived: sum of 2 quarters · filed 2022-02-11 | -$52.20M derived: sum of 3 quarters · filed 2022-02-11 | -$31.20M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2019-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | -$35.70M derived: sum of 2 quarters · filed 2022-02-11 | -$14.70M derived: sum of 3 quarters · filed 2022-02-11 | -$13.00M 10-K · filed 2022-02-11 | -$12.99M 10-K · filed 2020-02-07 | ||
| 2019-09-30 | -$28.50M 10-Q · filed 2020-11-09 | -$28.45M 10-Q · filed 2019-11-04 | -$7.50M derived: sum of 2 quarters · filed 2020-11-09 | -$5.80M 10-Q · filed 2020-11-09 | -$5.80M 10-Q · filed 2019-11-04 | ||
| 2019-06-30 | $21.00M 10-Q · filed 2020-08-03 | $22.70M 10-Q · filed 2020-08-03 | |||||
| 2019-03-31 | $1.70M 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |